Peptide radiopharmaceutical applications

Details Peptide radiopharmaceutical applications Peptide radiopharmaceutical applications

1996-05-21

1999-11-16

Dees, Jose' G.

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

424 111, 424 165, 530311, A61K 5100, A61M 3614

Patent

active

059852402

ABSTRACT:
The invention relates to radiotherapy with somatostatin-derived peptides labeled with medically useful metal ions. The invention in particular provides for methods and reagents for labeling somatostatin-derived peptides with perrhenate, in which a solution including somatostatin-derived peptide analogue containing at least one disulfide bond is provided, the solution is reacted with stannous ions and with a radioisotope, wherein the stannous ions are sufficient to substantially reduce the disulfide bonds of the peptide and the radioisotope, and the radiolabeled somatostatin-derived peptide analogue recovered. Also provided are methods for regional administration of radiolabeled somatostatin-derived peptides, methods for enhanced regional retention of radiolabeled somatostatin-derived peptides, methods for treatment of arthritis using radiolabeled somatostatin derived peptides, and methods for stabilizing radiolabeled somatostatin derived peptides.

REFERENCES:
patent: 4424200 (1984-01-01), Crockford et al.
patent: 4427646 (1984-01-01), Olexa et al.
patent: 4479930 (1984-10-01), Hnatowich
patent: 4612302 (1986-09-01), Szabo et al.
patent: 4668503 (1987-05-01), Hnatowich
patent: 4732864 (1988-03-01), Tolman
patent: 4904642 (1990-02-01), Coy et al.
patent: 4986979 (1991-01-01), Morgan, Jr. et al.
patent: 5011676 (1991-04-01), Thakur
patent: 5021235 (1991-06-01), Pipes
patent: 5039662 (1991-08-01), Schasteen
patent: 5051641 (1991-09-01), Shochat et al.
patent: 5078985 (1992-01-01), Rhodes
patent: 5091514 (1992-02-01), Fritzberg et al.
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5102990 (1992-04-01), Rhodes
patent: 5128119 (1992-07-01), Griffiths
patent: 5162505 (1992-11-01), Dean et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5225180 (1993-07-01), Dean et al.
patent: 5225530 (1993-07-01), Bernardi et al.
patent: 5229490 (1993-07-01), Tam
patent: 5236903 (1993-08-01), Saiki et al.
patent: 5308603 (1994-05-01), Thakur
patent: 5328679 (1994-07-01), Hansen et al.
patent: 5371184 (1994-12-01), Rajagopolan et al.
patent: 5376356 (1994-12-01), Morgan, Jr.
patent: 5382654 (1995-01-01), Lyle et al.
patent: 5384113 (1995-01-01), Deutsch et al.
patent: 5405597 (1995-04-01), Dean et al.
patent: 5443815 (1995-08-01), Dean et al.
patent: 5443816 (1995-08-01), Zamora et al.
patent: 5460785 (1995-10-01), Rhodes et al.
patent: 5620675 (1997-04-01), McBride et al.
patent: 5632969 (1997-05-01), Flanagan et al.
patent: 5679318 (1997-10-01), Vanderheyden et al.
Fischman, A.J., et al., "A Ticket to Ride: Peptide Radiopharmaceuticals," J Nucl Med, vol. 34, No. 12, pp. 2253-2263 (1993).
Hynes, R.O., "Inegrins: Versatility, Modulation, and Signaling in Cell Adhesion," Cell, vol. 69, pp. 11-25 (1992).
Ill, C.R., et al., "Adhesion of Platelets to Laminin in the Absence of Activation," J Cell Bio, vol. 99, pp. 2140-2145, (1984).
Khaw, B.A., et al., "Technetium-99m Labeling of Antibodies to Cardiac Myosin Fab and to Human Fibrinogen," J Nucl Med, vol. 23, No. 11, pp. 1011-1019 (1982).
Knight, L.C., et al., "Thrombus Imaging with TC-99m Synthetic Peptides Reactive with Activated Platelets," J Nucl Med, vol. 31, No. 5, No. 209 Abstract (May 1990).
Kondo, M., et al., "Studies of Dimeric IMLF with High Chemotactic Activities," Peptides: Chemistry and Biology, JA Smith and JE Rivier, eds., ESCOM, Leiden, pp. 425-426 (1992).
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, et al: Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [1231-Tyr3]-octreotide; the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716-731, 1993.
Kraus, J, et al., "Cyclic Tetrameric Clusters of Chemotactic Peptides as Superactive Activators of Lysozyme Release from Human Meutrophils," Bilchem and Biophy Res Comm, vol. 124, No. 3, pp. 939-944 (1984).
Sonnenberg, A., et al., "Isolation of .differential.6.beta.1 Integrins from Platelets and Adherent Cells by Chromatography on Mouse Laminin Fragment E8 and Human Laminin Pepsin Fragment," Exp Cell Res, vol. 197, pp. 234-244 (1991).
Tandon, N.N. et al., "Interaction of Human Platelets with Laminin and Identification of 67 kDa Laminin Receptor on Platelets," Riochem J, vol. 2724, pp. 535-542 (1991).
Swanson, D., et al., "In-111 Laminin Peptide Fragments for Malignant Tumor Detection," J Nucl Med, 34, 231P Abstract (1993).
Wraight, E.P., et al., "The Use of Chelating Derivative of Alpha Melanocyte Stimulating Hormone for the Clinical Imaging of Malignant Melanoma," Brit J Rad, vol. 65, pp. 112-118 (1992).
Yamada, K.M., "Adhesive Recognition Sequences," J Biol Chem, vol. 266, No. 20, pp. 12809-12812 (1992).
Akers MJ, "Antioxidants in Pharmaceutical Products", J. of Paren. Sci. & Tech. 36: 222-228 (1982).
Ballinger J, et al., "Stabilization of 99mTc-Pyrophosphate Injection with Gentisic Acid", Eur. J. Nuc. Med. 6:153-154 (1981).
Bender H, et al, "Local and Regional Therapy of Tumors With 188Re-RC-160: Clinical Aspects", appearing in Radionuclides for Receptors, 1995 (published after filing date of parent application).
Cai RZ, et al., "Synthesis and biological activity of highly potent octapeptide analogs of somatostatin", Proc. Natl. Acad. Sci. USA, 83: 1896-1900 (1986).
Chinol M, et al., "Chemistry and Biological Behavior of Samarium-153 and Rhenium-186-Labeled Hydroxyapatite Particles: Potential Radiopharmaceuticals for Radiation Synovectomy", J. Nuc. Med., 34: 1536-1542 (1993).
Deutsch E, et al., "Radiation synovectomy revisited", Eur. J. Nuc. Med. 20:1113-1127 (1993).
Fioravanti A, et al., "Valutazione dell' efficacia della somatostatina per via intraarticolare in pazienti con artrite reumatoide", La Clin. Ter. 142: 453-457 (1993) (English abstract provided).
Matucci-Cerinic M, et al., "Gold Salts and Somatostatin: A New Combined Analgesic Treatment For Psoriatic Arthritis", Drugs Exp. Clin. Res. 18: 53-61 (1992).
Tofe AJ, et al., "In Vitro Stabilization of a Low-Tin Bone-Imaging Agent (99mTc--Sn-HEDP) by Ascorbic Acid", J. of Nuc. Med. 17: 820-825 (1976).
Tofe AJ, et al., "Gentisic Acid: A New Stabilizer for Low Tin Skeletal Imaging Agents: Concise Communication", J. of Nuc. Med. 21: 366-370 (1979).
Will R, et al., "Comparison of two yttrium-90 regimens in inflammatory and osteoarthropathies", Ann. Rheum. Dis. 51: 262-265 (1993).
Zamora PO, et al., "Experimental Radiotherapy of Receptor-Positive Human Prostate Adenocarcinoma With 188Re-RC-160, A Directly-Radiolabeled Somatostatin Analogue", Int. J. Cancer 65: 214-220 (1996).
Bard, D.R., et al., "BisMSH-DTPA: A Potential Imaging Agent for Malignant Melanoma," Ann NY Acad Sci. 680, pp. 451-453 (1993).
Bard, D.R., et al., "A Chelating Derivative of a-Melanocyte Stimulating Hormone as a Potential Imaging Agent for Malignant Melanoma," Br J Cancer, vol. 62, pp. 919-922 (1990).
Cox, P.H., et al., "Technetium Labelled Somatostatin A Potential Agent for In Vivo Tumour Localization," 7th Int'l Sumpos on Radiopharm., p. 16 (1991) Abstract.
Pinski J, Shally AV, Halmos G, Szepeshazi K and Groot K: Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res 54:5895-5901, 1994.
Oberg K: Treatment of neuroendocrine tumors. Cancer Treat Rev 20:331-335, 1994.
Hoefnagel CA: Anti-cancer radiopharmaceuticals. Anticancer Drugs 2:107-32, 1991.
Riva P, Arista A, Sturiale C, Franceschi G et al: Possibility of control of malignant gliomas by direct intratumour or intralesional radioimmunotherapy (Abstract). J Nuc Med 5:144P (Abst. No. 582), 1994.
Pinski J, Schally AV, Halmos G, Szepenazi K, Groot K, O'Byrne K, Cai RZ: Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice, Br J Cancer 70:886-892, 1994.
Riva P, Sturiale C, Arista A, et al,: Intralesional Radioimmunotherapy of Malignant Gliomas As Adjuvant Setting In Newly Diagnosed Tumour Or As Rescue Treatment In Recurrent Lesions (Abstract). J Nucl Med Abstract Book 5:213P (Abstract No. 955), 1995.
Bender H, Zamora PO, Biersack HJ: Scintigrap

Affiliated with

Also associated with

Rating

Peptide radiopharmaceutical applications does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide radiopharmaceutical applications, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide radiopharmaceutical applications will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1320486